Nils C Bergenhem

US Patent:

20100278812, Nov 4, 2010

Filed:

Jun 4, 2010

Appl. No.:

12/794629

Inventors:

Nils Bergenhem - Guilford CT, US
Lance Berman - Portsmouth NH, US

Assignee:

CPEX Pharmaceuticals, Inc. - Exeter NH

International Classification:

A61K 39/07
A61K 39/00
A61K 39/395
A61P 37/04

US Classification:

4241301, 4241841, 4242461

Abstract:

Compositions and methods for intranasal delivery of antigens for immunization of a mammal are disclosed. Antigens include, peptides, proteins, peptidomimetics, DNA, RNA, carbohydrates and phospholipids. The compositions contain at least one antigen and a permeation enhancer.

US Patent:

20220226243, Jul 21, 2022

Filed:

May 8, 2020

Appl. No.:

17/609258

Inventors:

- Södertälje, SE
Maria Wågberg - MöIndal, SE
Nils Bergenhem - Waltham MA, US

Assignee:

AstraZeneca AB - Södertälje

International Classification:

A61K 9/127
A61K 38/18
A61K 48/00
A61P 17/02

Abstract:

The disclosure relates to nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide. Aspects of the disclosure further relate to uses of nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide, for improving wound healing in a subject. Some aspects of the disclosure relate to the topical administration of nanoparticles comprising a lipid component and a modified RNA.

US Patent:

20220226438, Jul 21, 2022

Filed:

May 8, 2020

Appl. No.:

17/609579

Inventors:

- Södertälje, SE
Maria Wågberg - MöIndal, SE
Nils Bergenhem - Waltham MA, US

Assignee:

AstraZeneca AB - Södertälje

International Classification:

A61K 38/18
A61K 48/00
A61P 17/02
A61K 9/16
A61K 47/18
A61K 47/24
A61K 47/28

Abstract:

This disclosure relates to mRNA therapy for (i) the promotion and/or improvement of wound healing, (ii) the prevention and/or reduction of scar formation at a wound, (iii) the reduction of the visibility of a scar, and/or (iv) the treatment of epidermolysis bullosa. mRNAs for use in the invention, when intradermally (e.g., using microneedles) or topically administered in vivo, encode a wound healing polypeptide (e.g., a growth factor, a cytokine, a chemokine, a protease inhibitor, or a collagen).

US Patent:

20140128379, May 8, 2014

Filed:

Mar 29, 2012

Appl. No.:

14/007153

Inventors:

Nils Bergenhem - Guilford CT, US
Carl Reppucci - North Andover MA, US
Zhengmao Li - Newmarket NH, US

Assignee:

CPEX Pharmaceuticals, Inc. - Wilmington DE

International Classification:

A61K 31/5513
A61K 9/00

US Classification:

514221

Abstract:

The present invention provides pharmaceutical compositions for intranasal delivery of a benzodiazepine. The composition may contain a therapeutically effective amount of a benzodiazepine or a pharmaceutically acceptable salt thereof, and a permeation enhancer. The permeation enhancer may be propylene glycol or a Hsieh permeation enhancer. The present compositions have excellent bioavailability. After administration of the present compositions, therapeutically effective plasma levels of the benzodiazepine may be achieved rapidly. The present pharmaceutical composition may be used to treat a patient suffering from anxiety, epilepsy, insomnia, agitation, seizures, muscular disorders, alcohol dependence, and drug withdrawal.